Planova: Literature Request

In vitro study of a triple-secured von Willebrand factor concentrate
Mazurier, C., et al. (Laboratoire Français du Fractionnement et des Biotechnologies) Vox Sanguinis 86: 100-104 (2004).

Virus removal from hemoglobin solution using Planova Membrane
Naito, Y., et al. (Waseda University, Hokkaido Red Cross, and Tokyo Medical University) Journal of Artificial Organs 5: 141-145 (2002).

Inactivation and Clearance of Viruses During the Manufacture of High Purity Factor IX
Johnston, A., et al. (CSL Limited and Macfarlane Burnet Centre for Medical Research) Biologicals 28: 129-136 (2000).

Removal of Viruses from Human Intravenous Immune Globulin by 35 nm Nanofiltration
Troccoli, N., et al. (Massachusetts Biologic Laboratories and Biologic Research Faculty and Facility) Biologicals 26: 321-329 (1998).

Virus Removal Studies Using Nanofiltration Membranes<
O'Grady, J., et al. (MedImmune, Inc. and Biological Research Faculty and Facility) Dev Biol Stand. 88: 319-326 (1996).

Improved removal of viruslike particles from purified monoclonal antibody IgM preparation via virus filtration
Maerz, H., et al. (University of Leipzig, Humboldt-University/Charité, and Asahi Chemical Industry) Nature Biotechnology 14: 651-652 (1996).

Manufacturing process of Anti-thrombin III concentrate: viral safety validation studies and effect of column re-use on viral clearance
Morrica, A., et al. (Kedrion S.p.A. and Q-ONE Biotech Ltd) Biologicals 31: 165-173 (2003).

A new liquid intravenous immunoglobulin with three dedicated virus reduction steps: virus and prion reduction capacity
Poelsler, G., et al. (Baxter Bioscience) Vox Sanguinis 94: 184-192 (2008)

Large-scale production and properties of human plasma-derived activated Factor VII concentrate
Tomokiyo, K., et al. (Kaketsuken) Vox Sanguinis 84: 54-64 (2003).

Implementation of a 20-nm pore-size filter in the plasma-derived Factor VIII manufacturing process
Furuya, K., et al. (Japanese Red Cross Plasma Fraction Center) Vox Sanguinis 91: 119-125 (2006).

Viral safety of Nanogam®, a new 15 nm-filtered liquid immunoglobulin product
Terpstra, F., et al. (Sanquin and Finnish Red Cross Blood Service) Vox Sanguinis 90: 21-32 (2006).

A solvent/detergent-treated and 15-nm filtered factor VIII: a new safety standard for plasma-derived coagulation factor concentrates
Chtourou, S., et al. (LFB and NIBSC) Vox Sanguinis 92: 327-337 (2007).

Removal of small nonenveloped viruses by antibody-enhanced nanofiltration during the manufacture of plasma derivative
Kreil, T., et al. (Baxter BioScience) Transfusion 46: 1143-1151 (2006).

Clearance of dengue virus in the plasma-derived therapeutic proteins
Xie, Y., et al. (Advantek Serum Laboratories Limited and The Chinese University of Hong Kong) Transfusion 48: 1342-1347 (2008).

Development of a Highly Purified Multicomponent Leukocyte IFN-a Product
Tölö, H., et al. (Finnish Red Cross Blood Transfusion Service and Biomedical Center) Journal of Interferon and Cytokine Research 21: 913-920 (2001).

Nanofiltration of single plasma donations: feasibility study
Burnouf, T., et al. (Human Plasma Product Services, Asahi Kasei Corporation, El-Shabrawishy Blood Bank, Cairo University, and St Thomas' Hospital) Vox Sanguinis 84: 111-119 (2003).

A Two-Column Process to Purify Antibodies Without Protein A
Ferreira, G., et al. (Medarex, Inc.) BioPharm International (2007).